PLx Pharma Inc. (PLXPQ)
| Market Cap | 2.49M |
| Revenue (ttm) | 4.54M |
| Net Income (ttm) | -27.58M |
| Shares Out | 28.60M |
| EPS (ttm) | -0.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 50,382,179 |
| Open | n/a |
| Previous Close | 0.0870 |
| Day's Range | 0.0825 - 0.1555 |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About PLXPQ
PLx Pharma Winddown Corp. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 m... [Read more]
Full Company ProfileFinancial Performance
In 2021, PLx Pharma's revenue was $8.21 million, an increase of 27260.00% compared to the previous year's $30,000. Losses were -$48.65 million, 187.1% more than in 2020.
Financial StatementsNews
PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets
SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-vali...
PLx Pharma Inc. Receives Nasdaq Delisting Notice
SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-vali...
PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update
- Significant Reduction in Operating Expenses
PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update
SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-valida...
Baseball Legend John Smoltz Featured on PLx Pharma's Social Channels
Legendary Baseball Pitcher and Avid Golfer Uses VAZALORE® 325 mg for Fast, Effective Pain Relief Legendary Baseball Pitcher and Avid Golfer Uses VAZALORE® 325 mg for Fast, Effective Pain Relief
Survey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mg
Results of National Patient Experience Survey Show 95% Satisfaction Rate
PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update
- Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value
PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update
SPARTA, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-valida...
PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions
VAZALORE Featured in Prominent Publication as Promising Alternative to Current Aspirin Options for Secondary Prevention of Cardiac Events VAZALORE Featured in Prominent Publication as Promising Altern...
PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update
BUILDING A SOLID BASE OF VAZALORE ® USERS
PLx Pharma Inc. to Discuss 2022 First Quarter Financial Results on May 13, 2022 Conference Call and Provide Business Update
SPARTA, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-valid...
PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update
Momentum Building for Novel Vazalore ® Liquid-Filled Aspirin Capsules
PLx Pharma Inc. to Present at Oppenheimer & Co's 32nd Annual Healthcare Conference on March 15, 2022
SPARTA, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-valid...
PLx Pharma Inc. to Discuss 2021 Fourth Quarter Financial Results on March 11, 2022 Conference Call and Provide Business Update
SPARTA, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-valida...
PLx Pharma Inc. Proudly Celebrates Go Red for Women Day® 2022 to Support Heart Health Awareness
-- Female-Led Company Strives to Transform Standard of Care in Secondary Prevention of Heart Attack or Clot-Related Stroke with its Innovative New Aspirin Formulation VAZALORE ® -- SPARTA, N. J., Fe...
PLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice President, Investor Relations & Corporate Communications
SPARTA, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-valid...
PLx Pharma Inc. to Present at Piper Sandler 33rd Annual Healthcare Conference 2021
SPARTA, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-valida...
PLx Pharma Inc. Reports Third Quarter 2021 Results and Provides Business Update
-- Results demonstrate strong execution of initial phase of VAZALORE commercial launch, including shipments to 30,000+ stores nationwide and e-commerce sites -- -- Reported net revenue of $6.6 million...
PLx Pharma Inc. Announces New Scientific Data Available Evaluating the Pharmacologic Profile of FDA-Approved VAZALORE 81 mg Liquid-Filled Aspirin Capsules
-- VAZALORE 81 mg shows fast bioavailability, absorption, and platelet inhibition -- -- VAZALORE 81 mg has pharmacokinetic and pharmacodynamic profiles consistent withVAZALORE 325 mg --
PLx Pharma Inc. to Discuss 2021 Third Quarter Financial Results on November 12, 2021 Conference Call and Provide Business Update
SPARTA, N.J., Nov. 01, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a specialty pharmaceutical company focused on its clinically-validated and patent-protected ...
PLx Pharma Inc. Provides VAZALORE Launch Update
-- Supplied VAZALORE to 30,000+ stores nationwide and e-commerce sites -- -- Launch in line with expectations and exceptionally positive feedback from consumers and healthcare professionals received -...
PLx Pharma stock drops again, and company looks to clarify USPTF's recent comments about aspirin use
Shares of PLx Pharma Inc. PLXP, -9.41% dropped 9.2% in afternoon trading Thursday, but nearly halved their earlier loss, as the drug maker responded to recently raised concerns over the use of aspirin...
PLx Pharma, Inc. Issues Statement on Recent USPTF Recommendations on Aspirin Therapy for Primary Prevention of Cardiovascular Disease; PLx's VAZALORE Specifically Indicated for Secondary Prevention
Aspirin remains an established practice for the prevention of another heart attack or clot-related stroke Aspirin remains an established practice for the prevention of another heart attack or clot-rel...
PLx Pharma Inc. to Present at Upcoming Virtual Healthcare Industry Conferences
SPARTA, N.J., Sept. 09, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PL...
PLx Pharma Inc.'s VAZALORE™ Now on Shelves; National Media Campaign Launches Today
-- Executing broad reach television advertising to support the launch of VAZALORE -- -- Media campaign reach matches extensive distribution at retailers --